歐洲MRD（微量殘存疾病）檢測市場－分析與預測（2023-2033）

根據預測，歐洲MRD（微量殘存疾病）檢測市場規模預計將從2023年的4.2億美元增加至2033年的17.4億美元，2023-2033年預測期間複合年成長率為15.19%。

由於多種因素，包括 MRD 檢測醫療保險覆蓋範圍的擴大及其在固態腫瘤診斷中的應用，MRD 檢測市場不斷成長。隨著消費者意識的增強，最近對 MRD 檢測的需求也有所增加。醫療保健專業人士和研究人員已經認知到這一轉變，並正在努力將 MRD 檢測涵蓋臨床程序，以滿足患者的需求。

主要市場統計數據
預測期	2023-2033
2023年評估價值	4.2億美元
2033年預測	17.4億美元
複合年成長率	15.19%

由於聚合酶鍊式反應 (PCR)、次世代定序(NGS) 和流式細胞儀等先進技術的採用，歐洲 MRD 檢測市場正經歷顯著成長。這種方法在治療後殘留癌細胞的檢測和定量中發揮關鍵作用。 MRD檢測在歐洲廣泛應用，因為它可以讓醫療保健提供者仔細監測治療反應、評估復發風險、調整個體化治療策略，並作為臨床試驗的重要終點，具有臨床重要性。這種識別和解決微量殘存疾病的主動方法將使整個歐洲醫療機構的醫療保健專業人員能夠改善結果並提高患者的生存率。人們對 MRD 檢測重要性的日益認知預計將繼續擴大全部區域的市場。

該報告考察了歐洲 MRD 測試市場，並提供了市場概述，包括最終用戶、地區和進入市場的公司概況的趨勢。

目錄

執行摘要

第1章 市場

• 市場範圍
• 調查方法
• 市場估算模型

第2章 市場概況

• MRD檢查流程分析
• MRD 檢測：固態腫瘤與骨髓惡性腫瘤
• MRD 檢測的演變
• 市場概況
• 市場規模及未來成長潛力

第3章業界考察

• MRD 檢測的法律和法律規範
  • 歐洲
  • 歐洲聯盟
• 供應鏈分析
  • 實驗室開發測試 (LDT)
  • 體外診斷（IVD）

第4章 MRD 檢測市場（按地區），2022-2033

• 概述
• 歐洲
  • 歐洲 MRD 檢測市場，依最終用戶分類
  • 歐洲 MRD 檢測市場（按國家）

第5章 公司簡介

• MRD Testing Ecosystem Active Players
• Cergentis BV
• F. Hoffmann-La Roche Ltd.
• ICON plc

“The Europe MRD Testing Market Expected to Reach $1.74 Billion by 2033.”

Introduction to Europe MRD Testing Market

The Europe MRD testing market is projected to reach $1.74 billion by 2033 from $0.42 billion in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033. The MRD testing market is experiencing growth due to various factors, such as the extension of medicare coverage for MRD testing and its utilization in diagnosing solid tumors. With the rise in consumer awareness, there is a growing demand for MRD testing in recent times. Healthcare professionals and researchers are acknowledging this shift and working towards incorporating MRD testing into clinical procedures to meet patient demands.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$0.42 Billion
2033 Forecast	$1.74 Billion
CAGR	15.19%

Market Introduction

The MRD testing market in Europe is witnessing significant growth, driven by the adoption of advanced techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry. This approach plays a pivotal role in the detection and quantification of residual cancer cells post-treatment. MRD testing holds clinical importance in Europe as it enables healthcare providers to closely monitor treatment response, assess the risk of relapse, tailor personalized therapeutic strategies, and serves as a crucial endpoint in clinical trials. This proactive approach to identifying and addressing minimal residual disease empowers healthcare professionals to aim for improved treatment outcomes and enhanced patient survival rates across the European healthcare landscape. The growing recognition of MRD testing's significance is expected to drive continued expansion in this market throughout the region.

Market Segmentation:

Segmentation 1: by End User

• Hospitals and Speciality Clinics
• Research Institutions
• Diagnostic Laboratories
• Other End Users

Segmentation 2: by Region

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Growth/Marketing Strategy: The Europe MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market.

Competitive Strategy: Key players in the Europe MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. MRD Testing Market: Research Methodology
  • 1.2.2. Data Sources
• 1.3. Market Estimation Model
  • 1.3.1. Criteria for Company Profiling

2. Market Overview

• 2.1. MRD Testing Workflow Analysis
• 2.2. MRD Testing: Solid Tumor vs. Hematological Malignancy
• 2.3. Evolution of MRD Testing
• 2.4. Market Footprint
• 2.5. Market Size and Future Growth Potential

3. Industry Insights

• 3.1. Legal and Regulatory Framework of MRD Tests
  • 3.1.1. Europe
  • 3.1.2. European Union
• 3.2. Supply Chain Analysis
  • 3.2.1. For Laboratory Developed Tests (LDTs)
  • 3.2.2. For In-Vitro Diagnostics (IVDs)

4. Minimal Residual Disease Testing Market (by Region), 2022-2033

• 4.1. Overview
• 4.2. Europe
  • 4.2.1. Europe MRD Testing Market, by End User
  • 4.2.2. Europe MRD Testing Market, by Country

5. Company Profiles

• 5.1. Overview
• 5.2. MRD Testing Ecosystem Active Players
• 5.3. Cergentis B.V.
  • 5.3.1. Company Overview
  • 5.3.2. Role of Cergentis B.V. in the MRD Testing Market
  • 5.3.3. Analyst Perspective
• 5.4. F. Hoffmann-La Roche Ltd.
  • 5.4.1. Company Overview
  • 5.4.2. Role of F. Hoffmann-La Roche Ltd in the MRD Testing Market
  • 5.4.3. Financials
  • 5.4.1. Recent Developments
  • 5.4.2. Analyst Perspective
• 5.5. ICON plc
  • 5.5.1. Company Overview
  • 5.5.2. Role of ICON plc in the MRD Testing Market
  • 5.5.3. Financials
  • 5.5.4. Analyst Perspective

List of Figures

• Figure 1: Europe MRD Testing Market, $Billion, 2022 and 2033
• Figure 2: Share of Europe MRD Testing Market (by End User), $Billion, 2022 and 2033
• Figure 3: Share of MRD Testing Market (by Region), 2022
• Figure 4: MRD Testing Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: MRD Testing Workflow
• Figure 9: Evolution of the MRD Testing Market
• Figure 10: Europe MRD Testing Market Potential, $Billion, 2022-2033
• Figure 11: Laboratory Methods for MRD Detection
• Figure 12: Supply Chain Analysis of Laboratory-Developed Tests
• Figure 13: Supply Chain Analysis of In-Vitro Diagnostics
• Figure 14: MRD Testing Market Snapshot (by Region)
• Figure 15: Europe MRD Testing Market, $Billion, 2022-2033
• Figure 16: Europe: Market Dynamics
• Figure 17: Europe MRD Testing Market (by End User), $Million, 2022-2033
• Figure 18: Europe MRD Testing Market (by Country), $Million, 2022-2033
• Figure 19: Germany MRD Testing Market, $Million, 2022-2033
• Figure 20: France MRD Testing Market, $Million, 2022-2033
• Figure 21: U.K. MRD Testing Market, $Million, 2022-2033
• Figure 22: Italy MRD Testing Market, $Million, 2022-2033
• Figure 23: Spain MRD Testing Market, $Million, 2022-2033
• Figure 24: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
• Figure 25: MRD Testing Market, Total Number of Companies Profiled
• Figure 26: Cergentis B.V.: Product Portfolio
• Figure 27: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 28: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
• Figure 29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
• Figure 30: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
• Figure 31: ICON plc: Product Portfolio
• Figure 32: ICON plc: Overall Financials, $Million, 2019-2021
• Figure 33: ICON plc: Revenue (by Region), $Million, 2019-2021

List of Tables

• Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Europe MRD Testing Market
• Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
• Table 3: Comparison of FDA and EMA Draft Guidance